Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (January 2017)
26 slides from Bionik Laboratories's investor presentation, Jan 30, 2017
Slide 1: Investor Presentation January 2017
LABORATOR Advanced robotic products for suffe oF Presentation January 2017
Slide 2: Legal Disclaimer
Legal Disclaimer ‘This presentation contains forward-looking statements relating to future events or the future financial performance and ‘operations of Bionik. Forward-looking statements, which involve assumptions and describe Bionik’s intent, belief or current expectations about its business oppor
Slide 3: Corporate Overview
Corporate Overview + Founded in 2011 (Toronto) Primary program exoskeleton assistive technology (ARKE) + Acquired interactive Motion Technologies (Boston) April 2016 Founded in 1998 by two MIT preeminent leaders in robots technology + MIT designed, industry leading patented technology *+ Proprietary
Slide 4: Our Goal
Our Goal To be the leading robotic medical technology company offering complete neurologic impairment solutions from hospital to home SR + Substantial year-over-year revenue growth to profitability in S years * Grow organically through innovative internal product development + Further grow through p
Slide 5: Bionik Investment Highlights
Bionik Investment Highlights BIONIK LABORATORIES
Slide 6: Stroke is a Global Epidemic
Stroke is a Global Epidemic Key Challenges + #1 Cause of serious, long-term disability worldwide + Globally 16 Million new patients annually - will double by 2030 and double again by 2050 Key Healthcare Trends + Effective treatments required as reimbursement shifts to patient outcomes rather than vo
Slide 7: Bionik Robots Improve Outcomes vs. Conventional Therapies
Bionik Robots Improve Outcomes vs. Conventional Therapies y Conventional jal *+ Focuses on habitual movement ~ repetition of a few functional motor skills + Treatment protocols are non-reproducible * Difficult to quantify true recovery *+ Low intensity - 25 to 45 movements per session Focuses on red
Slide 8: Products Commercially Available
Products Commercially Available 7 oday InMotion ARM™ ~ Designed to rehabilitate stroke patients with upper body neurological limitations ~ Interactive technology that continuously adapts and challenges the patient's ability Allows the clinician to efficiently deliver personalized intensive sensorimo
Slide 9: Development Products
Development Products + ARKE Lower Body Exoskeleton — For Clinic and Home {Clinic model provides lower extremity rehabilitation forthe neurotically impaired during inpatient stay ~ Home model provides assistance forthe mobilty impaired, in Both the healthcare neuro) and consumer (the 2668) Cloud anal
Slide 10: Robust Product Portfolio
Robust Product Portfolio ‘ ‘Commercial Launch F N File FOA Clearance % | ‘Commercial
Slide 11: Bionik Robots Clinically and Economically Proven
Bionik Robots Clinically and Economically Proven Stroke Veteran Affairs Healthcare System clinical trial Technology developed by Or. Hermano Krebs and RG Dr. Neville Hogan — leaders in medical robotics* + Over 200 published papers reviewing Bionik’s using Bionik’s Products* products + 25% reduction
Slide 12: The Bionik Advantage
The Bionik Advantage InMotion technology assists the healthcare provider to: + Treat based on neuro science principles, not only functional movements + Delivers progressive “assist-as-needed” individualized treatment plans + Precisely reproducible and measureable treatment protocols, + Provides high
Slide 13: This is a Big Opportunity
This is a Big Opportunity 2017 2018 Europe Units 4620 225000 0 30,000 OW Unt 4300 450,000 4620 e000 ‘ANNUAL UNITS ‘8.100 ‘900,000 2700 120,000 | Cc ace ioe B 3
Slide 14: Bionik Clinical Data Prompts Stroke Treatment Guidelines
Bionik Clinical Data Prompts Stroke Treatment Guidelines Stroke a + Referencing Bionik’s clinical trials, AHA’s Stroke Division assigned highest recommendation level for robot assisted therapy for upper extremity motor rehabilitation of moderate to severe stroke patients + VA stroke rehabilitation g
Slide 15: Additional Data to Drive Reimbursement and Market Expansion
Additional Data to Drive Reimburs: and Market Expansion + Funded by the research arm of the National Health Service (NHS), the largest and oldest single-payer healthcare system in the world + Exclusively uses Bionik’s upper body products “This is currently the best available technology for ‘robot as
Slide 16: U.S. Installations and High Profile Partnerships
U.S. Installations and High Profile and Partnerships (GW Northeast Health | ee Hues
Slide 17: InMotion Robots Installed in Countries
InMotion Robots Installed in 20 Countrie women —cimatay ee = fork SERS ean ey Pe a nn od -” > So Kore — entamaen granguavnny Sto” Sears i See tert
Slide 18: Bionik Expects to Lead the Market
ik Expects to Lead the Mart Access wi La Commercial strategies Broad product range (ea toexpand access AN onnaaren ‘ ania sno a o® A stennorotance a ‘Manufacturing & Asian Channel Strategy Ese) UK Study (2018) A 4 @>>>>e Outcomes (Clinical Data)
Slide 19: Sales Strategy
Sales Strategy + US-based sales team with four regional sales managers + Team has decades of successful track record selling high tech capital solutions into the rehab marketplace and are comfortable working “hands on” with therapists and patients * In Asia and Europe, we will secure strong distribu
Slide 20: Growth Strategy
Growth Strategy Expanded and velopment P * Building sales and distribution channels * Building new revenue models + Securing strategic investors and partners in key markets * Building pipeline organically and through licensing/acquisitions + Leveraging MIT relationships to expand product portfolio
Slide 21: Management Team
Management Team + Peter Bloch, CPA, CA~ Chief Executive Officer * Over 25 yes of executive management experience wth powen track recat of bung public and cate technaogy companies. Former FO 'nd ont lnterim CEO of Sano Canad, FO of intel, Gen TSGNM n/a Semtech NASOAG'SMTC), us Enagy(NYSE/TSLIE: nd Fo
Slide 22: Board and Advisors Strengthen
Board and Advisors Strengthen Board of Directors +e Robert Hartt independent Detar + Ohaiman Founder, Chit Scenic Ofer ad former Chef recov Ofice of Ceigene Celular Therspeutes: Board ‘member of Myos Corporation an Powsta Dagreses + Mare Mathie + independent Otector + het Makesing fcr of samsung Nor
Slide 23: Financial Snapshot
Financial Snapshot - OTCQX: BNKL Stock Ticker Symbol OTCOX: BNKL Market Capitalization as of January 26, 2017 $67.45 M Shares Outstanding* 964M. Warrants at exercise price of $1.40 164M Warrants at exercise price of $0.80 Cash as of September 30, 2016 ‘Amount received in grants to date
Slide 24: Execution of Near-Term Priorities Expected to Drive Value
Execution of Near-Term Priorities Expected to Drive Value Focus on revenue generation and market expansion Launch of AHW Version Uplist to National Exchange >>
Slide 25: Investment Summary
Investment Summary Ge 7 BIONIK LABORATORIES Proprietary robotics product line focused on stroke rehabilitation and assistive technology solutions Positioning to lead emerging market addressing $11 billion addressable market Proven clinical evidence differentiates product portfolio and puts Bionik in
Slide 26: Slide 26
Bionik Laboratories — Investor Presentation (January 2017) on 6ix